SRR934973
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934905 | — | — | 0.934 |
| 2 | BS_HHPA8NJ2 | medulloblastoma | — | 0.929 |
| 3 | TCGA-BB-4223-01A-01R-1436-07 | — | — | 0.927 |
| 4 | SRR934972 | — | — | 0.923 |
| 5 | BS_VVFBW0YH | medulloblastoma | — | 0.922 |
| 6 | BS_W311713R | medulloblastoma | — | 0.920 |
| 7 | SRR934771 | — | — | 0.914 |
| 8 | MNG1288 | — | — | 0.909 |
| 9 | C3L-02616 | — | cohortMD1 | 0.905 |
| 10 | BS_S1M423AB | Embryonal tumors | — | 0.903 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.383 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.353 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.228 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.123 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.103 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.060 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.049 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.005 | Idelalisib | — uncovered |